Experimental preemptive immunotherapy of murine cytomegalovirus disease with CD8 T-cell lines specific for ppM83 and pM84, the two homologs of human cytomegalovirus tegument protein ppUL83 (pp65).
about
Control of murine cytomegalovirus infection by γδ T cellsSystemic priming-boosting immunization with a trivalent plasmid DNA and inactivated murine cytomegalovirus (MCMV) vaccine provides long-term protection against viral replication following systemic or mucosal MCMV challengeHighly protective in vivo function of cytomegalovirus IE1 epitope-specific memory CD8 T cells purified by T-cell receptor-based cell sortingCD4+ T-cell reconstitution reduces cytomegalovirus in the immunocompromised brainTwo antigenic peptides from genes m123 and m164 of murine cytomegalovirus quantitatively dominate CD8 T-cell memory in the H-2d haplotype.Development of a vaccine against murine cytomegalovirus (MCMV), consisting of plasmid DNA and formalin-inactivated MCMV, that provides long-term, complete protection against viral replicationProcessing and presentation of murine cytomegalovirus pORFm164-derived peptide in fibroblasts in the face of all viral immunosubversive early gene functionsVigorous innate and virus-specific cytotoxic T-lymphocyte responses to murine cytomegalovirus in the submaxillary salivary gland.Reverse genetics modification of cytomegalovirus antigenicity and immunogenicity by CD8 T-cell epitope deletion and insertion.Lymphoma cell apoptosis in the liver induced by distant murine cytomegalovirus infection.Salivary glands act as mucosal inductive sites via the formation of ectopic germinal centers after site-restricted MCMV infectionStrong CD8 T-cell responses following coimmunization with plasmids expressing the dominant pp89 and subdominant M84 antigens of murine cytomegalovirus correlate with long-term protection against subsequent viral challengeEvaluating Human T-Cell Therapy of Cytomegalovirus Organ Disease in HLA-Transgenic Mice.Preliminary evidence that the novel host-derived immunostimulant EP67 can act as a mucosal adjuvant.Subdominant CD8 T-cell epitopes account for protection against cytomegalovirus independent of immunodomination.Reconstitution of CD8 T Cells Protective against Cytomegalovirus in a Mouse Model of Hematopoietic Cell Transplantation: Dynamics and Inessentiality of Epitope Immunodominance.Multiple epitopes in the murine cytomegalovirus early gene product M84 are efficiently presented in infected primary macrophages and contribute to strong CD8+-T-lymphocyte responses and protection following DNA immunization.Parameters determining the efficacy of adoptive CD8 T-cell therapy of cytomegalovirus infection.Guinea pig cytomegalovirus GP84 is a functional homolog of the human cytomegalovirus (HCMV) UL84 gene that can complement for the loss of UL84 in a chimeric HCMV.Identification of cytomegalovirus-specific cytotoxic T lymphocytes in vitro is greatly enhanced by the use of recombinant virus lacking the US2 to US11 region or modified vaccinia virus Ankara expressing individual viral genes.Memory inflation during chronic viral infection is maintained by continuous production of short-lived, functional T cells.New genes from old: redeployment of dUTPase by herpesviruses.The efficacy of antigen processing is critical for protection against cytomegalovirus disease in the presence of viral immune evasion proteins.Cytomegalovirus misleads its host by priming of CD8 T cells specific for an epitope not presented in infected tissues.Maternal Immunity and the Natural History of Congenital Human Cytomegalovirus Infection
P2860
Q27322847-97D452E6-8E80-4EEE-8230-FA1A64AD32AFQ33551402-CBDBEB93-A8AB-4678-96C9-D645EA1394E5Q33755031-963B2DA2-63F3-416C-8A9E-22937FEDF0BEQ33908883-8DC2567F-B110-4EC9-852E-8EDD9ABA983CQ34327234-2BF3FF8C-51BB-44DD-9F19-4DEAFEE082F5Q34338715-723E33B2-CFC7-48E2-B5E1-04C7600FC4A6Q34339686-BD44183A-7942-4ADE-BC15-34B388FCC187Q34465970-A6174C03-597C-48EB-BAF9-40CAA6B4FDBEQ34495529-4688C0A8-DB3D-462B-8DDD-08566C321173Q34647659-06221907-7E57-4949-97EA-4FCE5F0F5FBAQ34813263-9A23B055-01CA-4476-AC40-C682C961E253Q34970937-1A169A3B-08D2-49BB-8286-6F77BB48E0E9Q35693349-50D38D3C-79A2-466C-9A3E-393B9081BB5CQ36315607-A8E9E034-819D-46FB-908B-F3732CBC3983Q36673260-B44E839F-5775-48A6-B788-67459ADAB9C9Q36999665-AE29DCCE-A48A-475E-A3CA-FA6F60A3FB12Q37567900-98C4F7FC-427A-401F-BEED-8CADD503A5DBQ38042835-A25157D9-EBF6-4B92-A3B2-ED710290541FQ39629189-27112A99-1D0F-4E8A-B8EA-03E5BCB7DA14Q41057170-071AD5CC-D193-4B18-B27C-9DD641B6F0D6Q41862309-A5B5527D-3770-4106-BB0B-F8A41864C92DQ41882488-80FF1DC6-825B-4B64-8619-192B55BC3A01Q41887918-7B8F87F8-A89B-4C7A-A62D-316D30FEDD21Q42753262-547BFA55-E3A3-43B4-93C9-4DC62CF732E7Q58801058-944262B1-CEDE-4426-87C5-045046E55EAB
P2860
Experimental preemptive immunotherapy of murine cytomegalovirus disease with CD8 T-cell lines specific for ppM83 and pM84, the two homologs of human cytomegalovirus tegument protein ppUL83 (pp65).
description
2001 nî lūn-bûn
@nan
2001 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Experimental preemptive immuno ...... egument protein ppUL83 (pp65).
@ast
Experimental preemptive immuno ...... egument protein ppUL83 (pp65).
@en
type
label
Experimental preemptive immuno ...... egument protein ppUL83 (pp65).
@ast
Experimental preemptive immuno ...... egument protein ppUL83 (pp65).
@en
prefLabel
Experimental preemptive immuno ...... egument protein ppUL83 (pp65).
@ast
Experimental preemptive immuno ...... egument protein ppUL83 (pp65).
@en
P2093
P2860
P1433
P1476
Experimental preemptive immuno ...... egument protein ppUL83 (pp65).
@en
P2093
Grzimek NK
Holtappels R
Pahl-Seibert MF
Reddehase MJ
P2860
P304
P356
10.1128/JVI.75.14.6584-6600.2001
P577
2001-07-01T00:00:00Z